IMPACT
- The device has been used by more than 800 patients undergoing treatment for drug-sensitive and drug resistant TB till date in Maharashtra & Gujarat.
- TMEAD’s health technology assessment was completed by IIPHG, Gandhinagar, showing high levels of treatment adherence in the TMEAD intervention group (99%) as compared to the control group (90%)
- The health technology assessment of TMEAD by Dept. of Health Research (DHR) revealed that treatment adherence is high with TMEAD compared to standard therapy of care for DS-TB patients and the intervention is cost-effective. The results have led to the device being recommended to the Central TB Division (CTD) for use in the NTEP. Based on DHR’s presentation to CTD, TMEAD will be required to be integrated in the Nikshay platform, which will allow reporting of patient treatment adherence on the platform and supplement TB case notification and monitoring efforts. Based on these positive outcomes, TMEAD is currently being recommended by CTD to the state
“TB requires a prolonged medication where the number of medicines are way too much for patients. The device acts like a digital nurse that reminds patients to take their medication and manages their daily dose. It also helps the healthcare workers support these patients better. IHF is the perfect platform to help early innovators (like us) in achieving their goals.”
Rahul Doshi and Nishad Halkarni, Co-founders of Sensedose Technologies
